Neuronetics Taps Healthcare Sales Veteran Robert Greene as SVP Sales
Event summary
- Robert Greene appointed Senior Vice President Sales at Neuronetics, effective June 1, 2026.
- Greene received an inducement grant of 200,000 restricted stock units, vesting over four years.
- Neuronetics operates Greenbrook TMS treatment centers offering NeuroStar Advanced Therapy and SPRAVATO.
- NeuroStar Advanced Therapy is FDA-cleared for multiple neurohealth conditions, including MDD.
The big picture
Neuronetics' appointment of Robert Greene underscores its focus on strengthening commercial operations amid growing competition in the neurohealth sector. The move comes as the company seeks to expand its market reach for NeuroStar Advanced Therapy and SPRAVATO, leveraging Greene's extensive experience in healthcare sales and capital equipment. The inducement grant reflects a strategic investment in long-term leadership stability.
What we're watching
- Commercial Strategy
- How Greene's healthcare sales experience will impact Neuronetics' market penetration and revenue growth.
- Execution Risk
- Whether the four-year vesting schedule for Greene's stock units aligns with Neuronetics' strategic timelines.
- Market Dynamics
- The pace at which Neuronetics can expand its Greenbrook TMS treatment centers and integrate SPRAVATO offerings.